Lv42
678 积分 2023-04-24 加入
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
8天前
已完结
Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
9天前
已完结
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study
9天前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
9天前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
9天前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
9天前
已完结
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
9天前
已完结
Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
14天前
已完结
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL
14天前
已完结
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL
15天前
已完结
皖公网安备34019202002308
